Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda announces takeover of Inviragen

Takeda announces takeover of Inviragen

9th May 2013

Takeda has announced that its subsidiary Takeda America Holdings is to acquire Inviragen, a privately-held biopharmaceutical company headquartered in Colorado.

Inviragen specialises in the research and development of innovative vaccines for emerging infectious diseases – including dengue and hand, foot and mouth disease – and has created a number of promising products.

Its lead candidate DENVax is a four-strain recombinant viral vaccine for the prevention of dengue infection that is currently undergoing phase II testing, while the firm has also created a recombinant chikungunya vaccine candidate that is in preclinical development.

Takeda has paid an upfront fee of $35 million (22.49 million pounds) for Inviragen, with future payments of up to US$215 million linked to the progress of clinical development and the achievement of key commercial milestones.

Dr Rajeev Venkayya, executive vice-president and head of Takeda's vaccine business division, said: "Today's announcement reinforces Takeda's commitment to develop innovative vaccines to fight some of the world’s most important infectious diseases."

Last month, the company joined the Global Health Innovative Technology Fund, a new Japan-based public-private partnership scheme that aims to develop new healthcare innovations for the developing world.ADNFCR-8000103-ID-801582953-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.